Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.

MLA

Demyan, Lyudmyla, et al. “Pancreatic Cancer Patient-Derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.” Annals of Surgery, vol. 276, no. 3, Sept. 2022, pp. 450–62. EBSCOhost, https://doi.org/10.1097/SLA.0000000000005558.

APA

Demyan, L., Habowski, A. N., Plenker, D., King, D. A., Standring, O. J., Tsang, C., St. Surin, L., Rishi, A., Crawford, J. M., Boyd, J., Pasha, S. A., Patel, H., Galluzzo, Z., Metz, C., Gregersen, P. K., Fox, S., Valente, C., Abadali, S., Matadial-Ragoo, S., & DePeralta, D. K. (2022). Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Annals of Surgery, 276(3), 450–462. https://doi.org/10.1097/SLA.0000000000005558

Chicago

Demyan, Lyudmyla, Amber N. Habowski, Dennis Plenker, Daniel A. King, Oliver J. Standring, Caitlin Tsang, Luce St. Surin, et al. 2022. “Pancreatic Cancer Patient-Derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.” Annals of Surgery 276 (3): 450–62. doi:10.1097/SLA.0000000000005558.